These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21174561)

  • 1. Role of tyrosine kinase inhibitors in tumor immunology.
    Nishioka Y; Aono Y; Sone S
    Immunotherapy; 2011 Jan; 3(1):107-16. PubMed ID: 21174561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.
    Seliger B; Massa C; Rini B; Ko J; Finke J
    Trends Mol Med; 2010 Apr; 16(4):184-92. PubMed ID: 20304705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
    Ozao-Choy J; Ma G; Kao J; Wang GX; Meseck M; Sung M; Schwartz M; Divino CM; Pan PY; Chen SH
    Cancer Res; 2009 Mar; 69(6):2514-22. PubMed ID: 19276342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cells in human cancer.
    Nagaraj S; Gabrilovich DI
    Cancer J; 2010; 16(4):348-53. PubMed ID: 20693846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice.
    Abe F; Younos I; Westphal S; Samson H; Scholar E; Dafferner A; Hoke TA; Talmadge JE
    Int Immunopharmacol; 2010 Jan; 10(1):140-5. PubMed ID: 19833232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses.
    Ning Y; Xu D; Zhang X; Bai Y; Ding J; Feng T; Wang S; Xu N; Qian K; Wang Y; Qi C
    Int J Cancer; 2016 Jun; 138(11):2713-23. PubMed ID: 26773960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.
    Lizée G; Radvanyi LG; Overwijk WW; Hwu P
    Clin Cancer Res; 2006 Aug; 12(16):4794-803. PubMed ID: 16914564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?
    Jackaman C; Nelson DJ
    Exp Gerontol; 2014 Jun; 54():53-7. PubMed ID: 24291067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting immune suppressing myeloid-derived suppressor cells in oncology.
    Kao J; Ko EC; Eisenstein S; Sikora AG; Fu S; Chen SH
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):12-9. PubMed ID: 20304669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
    Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
    Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication.
    Chaoul N; Fayolle C; Desrues B; Oberkampf M; Tang A; Ladant D; Leclerc C
    Cancer Res; 2015 Aug; 75(16):3279-91. PubMed ID: 26122844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells.
    Tian J; Ma J; Ma K; Guo H; Baidoo SE; Zhang Y; Yan J; Lu L; Xu H; Wang S
    Eur J Immunol; 2013 May; 43(5):1220-30. PubMed ID: 23424024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic targeting of cancer-induced immunosuppressive cells.
    Alizadeh D; Larmonier N
    Cancer Res; 2014 May; 74(10):2663-8. PubMed ID: 24778417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering and reversing tumor immune suppression.
    Motz GT; Coukos G
    Immunity; 2013 Jul; 39(1):61-73. PubMed ID: 23890064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerogenic semimature dendritic cells induce effector T-cell hyporesponsiveness by the activation of antigen-specific CD4+ CD25+ T-regulatory cells.
    Fu BM; He XS; Yu S; Hu AB; Ma Y; Wu LW; Tam NL; Huang JF
    Exp Clin Transplant; 2009 Sep; 7(3):149-56. PubMed ID: 19715524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies for solid tumors: current status and future perspectives.
    Stoffel A
    BioDrugs; 2010 Oct; 24(5):303-16. PubMed ID: 20649180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging understanding of myeloid cells as partners and targets in tumor rejection.
    Broz ML; Krummel MF
    Cancer Immunol Res; 2015 Apr; 3(4):313-9. PubMed ID: 25847968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro.
    Chen JF; Gao J; Zhang D; Wang ZH; Zhu JY
    Chin Med J (Engl); 2010 Apr; 123(7):942-8. PubMed ID: 20497692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D3-mediated alterations to myeloid dendritic cell trafficking in vivo expand the scope of their antigen presenting properties.
    Enioutina EY; Bareyan D; Daynes RA
    Vaccine; 2007 Jan; 25(7):1236-49. PubMed ID: 17092617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.